Fc-disabled anti-mouse CD40l antibodies retain efficacy in promoting transplantation tolerance

American Journal of Transplantation

Volumn 8, Issue 11, 2008, Pages 2265-2271

  Daley, S R ^a,b   Cobbold, S P ^a   Waldmann, H ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b Biology and Environment   (Australia)

Author keywords

Allograft tolerance; Anti CD154 monoclonal antibody; Antibodies; Transplant immunology; Transplant tolerance; Venous thromboembolism

Indexed keywords

CD40 LIGAND; FC RECEPTOR;

ALLOGENIC BONE MARROW TRANSPLANTATION; ALLOGRAFT; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; GRAFT SURVIVAL; HEAVY CHAIN; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; SKIN TRANSPLANTATION; THROMBOCYTE AGGREGATION;

ANIMALS; BLOOD PLATELETS; BONE MARROW TRANSPLANTATION; CD40 LIGAND; FEMALE; GLYCOSYLATION; IMMUNOSUPPRESSIVE AGENTS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED CBA; RATS; SKIN; SKIN TRANSPLANTATION; TRANSPLANTATION TOLERANCE;

EID: 53749095475     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2008.02382.x     Document Type: Article

References (56)

1. Kenyon NS, Chatzipetrou M, Masetti M et al. Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154. Proc Natl Acad Sci USA 1999 96 : 8132 8137.
2. Kirk AD, Burkly LC, Batty DS et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med 1999 5 : 686 693.
3. Kirk AD, Harlan DM, Armstrong NN et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci USA 1997 94 : 8789 8794.
4. Kawai T, Andrews D, Colvin RB, Sachs DH, Cosimi AB. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med 2000 6 : 114.
5. Boumpas DT, Furie R, Manzi S et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 2003 48 : 719 727.
6. Langer F, Ingersoll SB, Amirkhosravi A et al. The role of CD40 in CD40L- and antibody-mediated platelet activation. Thromb Haemost 2005 93 : 1137 1146.
7. Mirabet M, Barrabes JA, Quiroga A, Garcia-Dorado D. Platelet pro-aggregatory effects of CD40L monoclonal antibody. Mol Immunol 2008 45 : 937 944.
8. Monk NJ, Hargreaves RE, Marsh JE et al. Fc-dependent depletion of activated T cells occurs through CD40L-specific antibody rather than costimulation blockade. Nat Med 2003 9 : 1275 1280.
9. Ferrant JL, Benjamin CD, Cutler AH et al. The contribution of Fc effector mechanisms in the efficacy of anti-CD154 immunotherapy depends on the nature of the immune challenge. Int Immunol 2004 16 : 1583 1594.
10. Sohn JH, Bora PS, Suk HJ, Molina H, Kaplan HJ, Bora NS. Tolerance is dependent on complement C3 fragment iC3b binding to antigen-presenting cells. Nat Med 2003 9 : 206 212.
11. Woelbing F, Kostka SL, Moelle K et al. Uptake of Leishmania major by dendritic cells is mediated by Fcgamma receptors and facilitates acquisition of protective immunity. J Exp Med 2006 203 : 177 188.
12. Quezada SA, Bennett K, Blazar BR, Rudensky AY, Sakaguchi S, Noelle RJ. Analysis of the underlying cellular mechanisms of anti-CD154-induced graft tolerance: The interplay of clonal anergy and immune regulation. J Immunol 2005 175 : 771 779.
13. Nagelkerken L, Haspels I, van Rijs W et al. FcR interactions do not play a major role in inhibition of experimental autoimmune encephalomyelitis by anti-CD154 monoclonal antibodies. J Immunol 2004 173 : 993 999.
14. Noelle RJ, Roy M, Shepherd DM, Stamenkovic I, Ledbetter JA, Aruffo A. A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells. Proc Natl Acad Sci USA 1992 89 : 6550 6554.
15. Cobbold SP, Jayasuriya A, Nash A, Prospero TD, Waldmann H. Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo. Nature 1984 312 : 548 551.
16. Bruggemann M, Teale C, Clark M, Bindon C, Waldmann H. A matched set of rat/mouse chimeric antibodies. Identification and biological properties of rat H chain constant regions mu, gamma 1, gamma 2a, gamma 2b, gamma 2c, epsilon, and alpha. J Immunol 1989 142 : 3145 3150.
17. Isaacs JD, Clark MR, Greenwood J, Waldmann H. Therapy with monoclonal antibodies. An in vivo model for the assessment of therapeutic potential. J Immunol 1992 148 : 3062 3071.
18. Scully R, Cobbold SP, Mellor AL, Wissing M, Arnold B, Waldmann H. A role for Th2 cytokines in the suppression of CD8+ T cell-mediated graft rejection. Eur J Immunol 1997 27 : 1663 1670.
19. Gilliland LK, Walsh LA, Frewin MR et al. Elimination of the immunogenicity of therapeutic antibodies. J Immunol 1999 162 : 3663 3671.
20. Zelenika D, Adams E, Mellor A et al. Rejection of H-Y disparate skin grafts by monospecific CD4+ Th1 and Th2 cells: No requirement for CD8+ T cells or B cells. J Immunol 1998 161 : 1868 1874.
21. Gilliland LK, Norris NA, Marquardt H et al. Rapid and reliable cloning of antibody variable regions and generation of recombinant single chain antibody fragments. Tissue Antigens 1996 47 : 1 20.
22. Tao MH, Morrison SL. Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J Immunol 1989 143 : 2595 2601.
23. Qin SX, Wise M, Cobbold SP et al. Induction of tolerance in peripheral T cells with monoclonal antibodies. Eur J Immunol 1990 20 : 2737 2745.
24. Qin S, Cobbold S, Tighe H, Benjamin R, Waldmann H. CD4 monoclonal antibody pairs for immunosuppression and tolerance induction. Eur J Immunol 1987 17 : 1159 1165.
25. Wekerle T, Kurtz J, Ito H et al. Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment. Nat Med 2000 6 : 464 469.
26. Durham MM, Bingaman AW, Adams AB et al. Cutting edge: Administration of anti-CD40 ligand and donor bone marrow leads to hemopoietic chimerism and donor-specific tolerance without cytoreductive conditioning. J Immunol 2000 165 : 1 4.
27. Seung E, Mordes JP, Rossini AA, Greiner DL. Hematopoietic chimerism and central tolerance created by peripheral-tolerance induction without myeloablative conditioning. J Clin Invest 2003 112 : 795 808.
28. Graca L, Le Moine A, Lin CY, Fairchild PJ, Cobbold SP, Waldmann H. Donor-specific transplantation tolerance: The paradoxical behavior of CD4+CD25+ T cells. Proc Natl Acad Sci USA 2004 101 : 10122 10126.
29. Graca L, Daley S, Fairchild PJ, Cobbold SP, Waldmann H. Co-receptor and co-stimulation blockade for mixed chimerism and tolerance without myelosuppressive conditioning. BMC Immunol 2006 7 : 9.
30. Honey K, Cobbold SP, Waldmann H. CD40 ligand blockade induces CD4+ T cell tolerance and linked suppression. J Immunol 1999 163 : 4805 4810.
31. Xu H, Elster E, Batty D et al. Effects of dose and duration of anti-CD154 antibody therapy in preventing renal allograft rejection in a nonhuman primate model. Transplant Proc 2001 33 : 223 224.
32. Davies JD, Leong LY, Mellor A, Cobbold SP, Waldmann H. T cell suppression in transplantation tolerance through linked recognition. J Immunol 1996 156 : 3602 3607.
33. Wise MP, Bemelman F, Cobbold SP, Waldmann H. Linked suppression of skin graft rejection can operate through indirect recognition. J Immunol 1998 161 : 5813 5816.
34. Kanmaz T, Fechner JJ Jr., Torrealba J et al. Monotherapy with the novel human anti-CD154 monoclonal antibody ABI793 in rhesus monkey renal transplantation model. Transplantation 2004 77 : 914 920.
35. Schuler W, Bigaud M, Brinkmann V et al. Efficacy and safety of ABI793, a novel human anti-human CD154 monoclonal antibody, in cynomolgus monkey renal allotransplantation. Transplantation 2004 77 : 717 726.
36. Adams AB, Shirasugi N, Jones TR et al. Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival. J Immunol 2005 174 : 542 550.
37. Haanstra KG, Ringers J, Sick EA et al. Prevention of kidney allograft rejection using anti-CD40 and anti-CD86 in primates. Transplantation 2003 75 : 637 643.
38. Haanstra KG, Sick EA, Ringers J et al. Costimulation blockade followed by a 12-week period of cyclosporine A facilitates prolonged drug-free survival of rhesus monkey kidney allografts. Transplantation 2005 79 : 1623 1626.
39. Pearl JP, Xu H, Leopardi F, Preston E, Kirk AD. CD154 blockade, sirolimus, and donor-specific transfusion prevent renal allograft rejection in cynomolgus monkeys despite homeostatic T-cell activation. Transplantation 2007 83 : 1219 1225.
40. Preston EH, Xu H, Dhanireddy KK et al. IDEC-131 (anti-CD154), sirolimus and donor-specific transfusion facilitate operational tolerance in non-human primates. Am J Transplant 2005 5 : 1032 1041.
41. Xu H, Montgomery SP, Preston EH et al. Studies investigating pretransplant donor-specific blood transfusion, rapamycin, and the CD154-specific antibody IDEC-131 in a nonhuman primate model of skin allotransplantation. J Immunol 2003 170 : 2776 2782.
42. Morrison SL, Oi VT. Genetically engineered antibody molecules. Adv Immunol 1989 44 : 65 92.
43. Bolt S, Routledge E, Lloyd I et al. The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur J Immunol 1993 23 : 403 411.
44. Friend PJ, Hale G, Chatenoud L et al. Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection. Transplantation 1999 68 : 1632 1637.
45. Beilke JN, Kuhl NR, Kaer LV, Gill RG. NK cells promote islet allograft tolerance via a perforin-dependent mechanism. Nat Med 2005 11 : 1059 1065.
46. Daley SR, Ma J, Adams E, Cobbold SP, Waldmann H. A key role for TGF-beta signaling to T cells in the long-term acceptance of allografts. J Immunol 2007 179 : 3648 3654.
47. Larsen CP, Elwood ET, Alexander DZ et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996 381 : 434 438.
48. Markees TG, Phillips NE, Gordon EJ et al. Long-term survival of skin allografts induced by donor splenocytes and anti-CD154 antibody in thymectomized mice requires CD4(+) T cells, interferon-gamma, and CTLA4. J Clin Invest 1998 101 : 2446 2455.
49. Taylor PA, Lees CJ, Waldmann H, Noelle RJ, Blazar BR. Requirements for the promotion of allogeneic engraftment by anti-CD154 (anti-CD40L) monoclonal antibody under nonmyeloablative conditions. Blood 2001 98 : 467 474.
50. Ito H, Kurtz J, Shaffer J, Sykes M. CD4 T cell-mediated alloresistance to fully MHC-mismatched allogeneic bone marrow engraftment is dependent on CD40-CD40 ligand interactions, and lasting T cell tolerance is induced by bone marrow transplantation with initial blockade of this pathway. J Immunol 2001 166 : 2970 2981.
51. Sanchez-Fueyo A, Domenig C, Strom TB, Zheng XX. The complement dependent cytotoxicity (CDC) immune effector mechanism contributes to anti-CD154 induced immunosuppression. Transplantation 2002 74 : 898 900.
52. Andre P, Prasad KS, Denis CV et al. CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism. Nat Med 2002 8 : 247 252.
53. Leveille C, Bouillon M, Guo W et al. CD40 ligand binds to alpha5beta1 integrin and triggers cell signaling. J Biol Chem 2007 282 : 5143 5151.
54. Karpusas M, Lucci J, Ferrant J et al. Structure of CD40 ligand in complex with the Fab fragment of a neutralizing humanized antibody. Structure (Cambridge) 2001 9 : 321 329.
55. Blair PJ, Riley JL, Harlan DM et al. CD40 ligand (CD154) triggers a short-term CD4(+) T cell activation response that results in secretion of immunomodulatory cytokines and apoptosis. J Exp Med 2000 191 : 651 660.
56. Scully R, Qin S, Cobbold S, Waldmann H. Mechanisms in CD4 antibody-mediated transplantation tolerance: Kinetics of induction, antigen dependency and role of regulatory T cells. Eur J Immunol 1994 24 : 2383 2392.